ARCHIVES

Phase III Study Evaluating Halaven Fails To Meet Primary Endpoints

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

NCI, FDA Near Agreement On INDs; Young, Hoogstraten Clash On Rubidazone

January 14, 1977

The March: AACR, AACI Compile List Of Activities Related To The March

May 8, 1998

Hormone Therapy Can Reduce Survival In Men With Heart Problems

August 26, 2011

In Brief: Gifts to NCI Totaled $332,226 In Fiscal 1986; Position Freeze Said To Hurt DCE Labs

January 3, 1986

Hammer Gives $100,000 to Expand Rosenberg’s T-Cell Growth Factor Clinical Studies

March 1, 1985

Chemical Carcinogenesis

November 18, 1994